{"parse":{"title":"List of Guidances for Statistics in Regulatory Affairs","pageid":50970546,"revid":838265121,"text":{"*":"<div class=\"mw-parser-output\"><p>This List presents a comprehensive source of references for statistical guidance documents and related articles that are relevant to regulatory affairs for those statisticians that work on clinical studies.  The List is associated with the Wikipedia page <a href=\"/wiki/Guidances_for_statistics_in_regulatory_affairs\" title=\"Guidances for statistics in regulatory affairs\">Guidances for statistics in regulatory affairs</a> that aims to address the various topics of the listed guidances. Regulatory guidances (draft and/or final ) are subject to revisions. Therefore, users of the guidances are advised to consult the original website to check for the latest version. Users are also encouraged to update the Wikipedia List.\n</p>\n<div style=\"clear: right; margin-bottom: .5em; float: right; padding: .5em 0 .8em 1.4em; background: none; width: auto;\"><div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#References_classified_by_statistical_topic\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">References classified by statistical topic</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Good_clinical_practice\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Good clinical practice</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Data_monitoring_committees\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Data monitoring committees</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Adjustment_by_covariates\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Adjustment by covariates</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Small_populations_/_rare_diseases\"><span class=\"tocnumber\">1.4</span> <span class=\"toctext\">Small populations / rare diseases</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Extrapolation_/_bridging\"><span class=\"tocnumber\">1.5</span> <span class=\"toctext\">Extrapolation / bridging</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Non-inferiority\"><span class=\"tocnumber\">1.6</span> <span class=\"toctext\">Non-inferiority</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Subgroup_analysis\"><span class=\"tocnumber\">1.7</span> <span class=\"toctext\">Subgroup analysis</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Endpoints\"><span class=\"tocnumber\">1.8</span> <span class=\"toctext\">Endpoints</span></a></li>\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Marketing_authorization\"><span class=\"tocnumber\">1.9</span> <span class=\"toctext\">Marketing authorization</span></a></li>\n<li class=\"toclevel-2 tocsection-11\"><a href=\"#Missing_data\"><span class=\"tocnumber\">1.10</span> <span class=\"toctext\">Missing data</span></a></li>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#Multiplicity\"><span class=\"tocnumber\">1.11</span> <span class=\"toctext\">Multiplicity</span></a></li>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#Randomization\"><span class=\"tocnumber\">1.12</span> <span class=\"toctext\">Randomization</span></a></li>\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#Reporting\"><span class=\"tocnumber\">1.13</span> <span class=\"toctext\">Reporting</span></a></li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Study_design\"><span class=\"tocnumber\">1.14</span> <span class=\"toctext\">Study design</span></a></li>\n<li class=\"toclevel-2 tocsection-16\"><a href=\"#Method_validation\"><span class=\"tocnumber\">1.15</span> <span class=\"toctext\">Method validation</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-17\"><a href=\"#References_classified_by_special_populations\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">References classified by special populations</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-18\"><a href=\"#Gender\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Gender</span></a></li>\n<li class=\"toclevel-2 tocsection-19\"><a href=\"#Geriatrics\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Geriatrics</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-20\"><a href=\"#References_classified_by_therapeutic_area\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">References classified by therapeutic area</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-21\"><a href=\"#Chronic_obstructive_pulmonary_disease_(COPD)\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Chronic obstructive pulmonary disease (COPD)</span></a></li>\n<li class=\"toclevel-2 tocsection-22\"><a href=\"#Diabetes_mellitus\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Diabetes mellitus</span></a></li>\n<li class=\"toclevel-2 tocsection-23\"><a href=\"#Multiple_sclerosis_(MS)\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">Multiple sclerosis (MS)</span></a></li>\n<li class=\"toclevel-2 tocsection-24\"><a href=\"#Oncology\"><span class=\"tocnumber\">3.4</span> <span class=\"toctext\">Oncology</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-25\"><a href=\"#References_classified_as_Health_Technology_Assessment_(HTA)\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References classified as Health Technology Assessment (HTA)</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-26\"><a href=\"#EUnetHTA_guidelines\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">EUnetHTA guidelines</span></a></li>\n<li class=\"toclevel-2 tocsection-27\"><a href=\"#Methods_papers_of_HTA_agencies\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">Methods papers of HTA agencies</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-28\"><a href=\"#References_classified_as_country_specific\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References classified as country specific</span></a></li>\n<li class=\"toclevel-1 tocsection-29\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-30\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-31\"><a href=\"#External_links\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n</div>\n<h2><span class=\"mw-headline\" id=\"References_classified_by_statistical_topic\">References classified by statistical topic</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=1\" title=\"Edit section: References classified by statistical topic\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Good_clinical_practice\">Good clinical practice</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=2\" title=\"Edit section: Good clinical practice\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>ICH E6(R2): Good clinical practice <sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects.</li>\n<li>FDA: Good Review Practice: Clinical Review of Investigational New Drug Applications.<sup id=\"cite_ref-FDA-GRP_2-0\" class=\"reference\"><a href=\"#cite_note-FDA-GRP-2\">&#91;2&#93;</a></sup> This good review practice (GRP) document was prepared to assist FDA clinical review staff in reviewing clinical submissions to an investigational new drug application (IND) from the pre-IND phase to the time of the pre-new drug application/biologics license application meeting.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Data_monitoring_committees\">Data monitoring committees</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=3\" title=\"Edit section: Data monitoring committees\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>CHMP/EWP/5872/03: Data monitoring committees<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> (EMA) deals with independent data monitoring committees. It highlights the key issues involved when sponsors include data monitoring committees as a part of their trial management.</li>\n<li>FDA: Establishment and Operation of Clinical Trial Data Monitoring Committees.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> This guidance discusses the roles, responsibilities and operating procedures of Data Monitoring Committees (DMCs) (also known as Data and Safety Monitoring Boards (DSMBs) or Data andSafety Monitoring Committees (DSMCs)) that may carry out important aspects of clinical trial monitoring.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Adjustment_by_covariates\">Adjustment by covariates</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=4\" title=\"Edit section: Adjustment by covariates\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/CHMP/295050/2013: Adjustment for baseline covariates in clinical trials<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> (EMA) provides advice on how to address important baseline covariates in designing, analysing and reporting clinical trials. It mainly focuses on confirmatory randomised trials.</li></ul>\n<h3><span id=\"Small_populations_.2F_rare_diseases\"></span><span class=\"mw-headline\" id=\"Small_populations_/_rare_diseases\">Small populations / rare diseases</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=5\" title=\"Edit section: Small populations / rare diseases\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>CHMP/EWP/83561/05: Clinical trials in small populations<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup> (EMA) addresses problems associated with clinical trials when there are limited numbers of patients available to study.</li>\n<li>FDA <i>Rare diseases: Common issues in drug development</i>.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup> Guidance for industry.</li>\n<li>see also the <a href=\"/wiki/List_of_Guidances_for_Statistics_in_Regulatory_Affairs#Subgroup_analysis\" title=\"List of Guidances for Statistics in Regulatory Affairs\">subgroup analysis</a> section</li></ul>\n<h3><span id=\"Extrapolation_.2F_bridging\"></span><span class=\"mw-headline\" id=\"Extrapolation_/_bridging\">Extrapolation / bridging</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=6\" title=\"Edit section: Extrapolation / bridging\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/199678/2016: <i>Reflection paper on extrapolation of efficacy and safety in paediatric medicine development</i>.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup></li>\n<li>FDA <i>Leveraging existing clinical data for extrapolation to pediatric uses of medical devices</i>. Guidance for Industry and Food and Drug Administration Staff.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup></li>\n<li>ICH E5 (R1): <i>Ethnic factors in the acceptability of foreign clinical data</i>.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> This document addresses the intrinsic characteristics of the drug recipient and extrinsic characteristics associated with environment and culture that could affect the results of clinical studies carried out in regions and describes the concept of the \"bridging study\" that a new region may request to determine whether data from another region are applicable to its population.</li>\n<li>FDA <i>Use of real-world evidence to support regulatory decision-making for medical devices</i>. Guidance for Industry and FDA Staff.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup></li></ul>\n<h3><span class=\"mw-headline\" id=\"Non-inferiority\">Non-inferiority</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=7\" title=\"Edit section: Non-inferiority\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>CPMP/EWP/2158/99: Choice of a non-inferiority<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> (EMA) provides guidance on two types of non-inferiority trials: trials with two arms, the test product and a comparator; and three-armed trials with the test product, an active comparator and placebo.</li>\n<li>CPMP/EWP/482/99: Switching between superiority and non-inferiority<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup> (EMA) addresses the issues of superiority, non-inferiority and equivalence from the perspective of an efficacy trial with a single primary variable.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Subgroup_analysis\">Subgroup analysis</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=8\" title=\"Edit section: Subgroup analysis\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/CHMP/539146/2013: Investigation of subgroups in confirmatory clinical trials<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> (EMA) provides guidance for assessors in European regulatory agencies on assessment of subgroup analyses in confirmatory clinical trials.</li>\n<li>see also the <a href=\"/wiki/List_of_Guidances_for_Statistics_in_Regulatory_Affairs#Small_populations_/_rare_diseases\" title=\"List of Guidances for Statistics in Regulatory Affairs\">Small populations / rare diseases</a> section</li></ul>\n<h3><span class=\"mw-headline\" id=\"Endpoints\">Endpoints</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=9\" title=\"Edit section: Endpoints\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>FDA: Clinical trial endpoints for the approval of cancer drugs and biologics<sup id=\"cite_ref-fda.gov_15-0\" class=\"reference\"><a href=\"#cite_note-fda.gov-15\">&#91;15&#93;</a></sup> provides recommendations to applicants on endpoints for cancer clinical trials submitted to the Food and Drug Administration (FDA) to support effectiveness claims in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Marketing_authorization\">Marketing authorization</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=10\" title=\"Edit section: Marketing authorization\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>CPMP/EWP/2330/99: Application with 1. Meta-analyses; 2. One pivotal study<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> (EMA) provides guidance on two topics: the use of meta-analysis and the use of only a single pivotal study in phase III clinical development.</li>\n<li>ICH E1: Population exposure: the extent of population exposure to assess clinical safety<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup> presents an accepted set of principles for the safety evaluation of drugs intended for the long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening diseases.</li>\n<li>EMA/129698/2012: Extrapolation of efficacy and safety in medicine development<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup> (EMA) discusses the need and possibility to develop a framework for extrapolation approaches that are considered scientifically valid and reliable to support medicine authorisation.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Missing_data\">Missing data</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=11\" title=\"Edit section: Missing data\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>CPMP/EWP/1776/99: Missing data in confirmatory clinical trials<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup> (EMA) explains how the presence of missing data in confirmatory clinical trials should be addressed and reported in a dossier submitted for regulatory review. It provides an insight into the regulatory standards that will be used to assess confirmatory clinical trials with missing data.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Multiplicity\">Multiplicity</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=12\" title=\"Edit section: Multiplicity\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/286914/2012: Multiplicity issues in clinical trials<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup> (EMA) addresses the multiplicity in the clinical trials in the context of an application for marketing authorisation of a medicinal product.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Randomization\">Randomization</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=13\" title=\"Edit section: Randomization\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The randomization is discussed in:\n</p>\n<ul><li>FDA: Good Review Practice: Clinical Review of Investigational New Drug Applications,<sup id=\"cite_ref-FDA-GRP_2-1\" class=\"reference\"><a href=\"#cite_note-FDA-GRP-2\">&#91;2&#93;</a></sup> chapter 6.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Reporting\">Reporting</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=14\" title=\"Edit section: Reporting\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>ICH E3: Structure and content of clinical study reports<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> aims to allow the compilation of a single core clinical study report acceptable to all regulatory authorities of the ICH regions. Read together with questions and answers.</li>\n<li>FDA: Safety Reporting Requirements for INDs and BA/BE Studies.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> This guidance focuses on expedited safety reporting requirements for human drug and biological products that are being investigated under an IND and for drugs that are the subjects of bioavailability (BA) and bioequivalence (BE) studies that are exempt from the IND requirements.</li>\n<li>FDA: Adverse Event Reporting to IRBs.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup> This guidance focuses guidance provides recommendations for sponsors and investigators conducting IND trials to help them differentiate between those adverse events that are unanticipated problems that must be reported to an IRB and those that are not.</li>\n<li>FDA: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> This guidance is intended to assist applicants and other responsible parties in fulfilling the FDAs existing postmarketing safety reporting requirements for human marketed drug and biological products.</li>\n<li>ICH E2F: Development Safety Update Report.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> (DSUR) is intended to be a common standard for periodic reporting on drugs under development (including marketed drugs that are under further study) among the ICH regions.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Study_design\">Study design</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=15\" title=\"Edit section: Study design\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>ICH E4: Dose response information to support drug registration<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> provides guidance on obtaining dose-response information. It describes the study designs for assessing dose-response.</li>\n<li>ICH E5 (R1): Ethnic factors in the acceptability of foreign clinical data<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup> recommends a framework for evaluating the impact of ethnic factors upon a medicine\u2019s effect, i.e., its efficacy and safety at a particular dosage and dose regimen. Read together with questions and answers.</li>\n<li>ICH E9: Statistical principles for clinical trials<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> section III provides a general overview of common  designs in clinical trials.</li>\n<li>ICH E10: Choice of control group in clinical trials<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup> describes the general principles involved in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment and to discuss related trial design and conduct issues.</li>\n<li>CHMP/EWP/2459/02: Methodological issues in confirmatory clinical trials planned with an adaptive design<sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup> (EMA) focuses on the opportunities for interim trial design modifications, and the prerequisites, problems and pitfalls that must be considered as soon as any kind of flexibility is introduced into a confirmatory  clinical trial intended to provide evidence of efficacy.</li>\n<li>FDA: Adaptive Design Clinical Trials for Drugs and Biologics.<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup> This guidance focuses on information regarding adaptive design clinical trials when used in drug development programs.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Method_validation\">Method validation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=16\" title=\"Edit section: Method validation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMEA/CHMP/EWP/192217/2009: EMA Guideline on bioanalytical method validation.<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup> This guideline defines key elements necessary for the validation of bioanalytical methods.</li></ul>\n<p><br />\n</p>\n<h2><span class=\"mw-headline\" id=\"References_classified_by_special_populations\">References classified by special populations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=17\" title=\"Edit section: References classified by special populations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Gender\">Gender</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=18\" title=\"Edit section: Gender\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>FDA: Evaluation of Sex-Specific Data in Medical Device Clinical Studies <sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> provides guidance on the study and evaluation of sex-specific data in medical device clinical studies.</li></ul>\n<h3><span class=\"mw-headline\" id=\"Geriatrics\">Geriatrics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=19\" title=\"Edit section: Geriatrics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>ICH E7: Studies in support of special populations: geriatrics <sup id=\"cite_ref-34\" class=\"reference\"><a href=\"#cite_note-34\">&#91;34&#93;</a></sup> addresses the clinical evaluation of medicinal products in geriatric populations. It gives special consideration to the differences in pharmacokinetic, pharmacodynamic and dose response studies in elderly patients. It also covers drug drug interaction studies.</li></ul>\n<h2><span class=\"mw-headline\" id=\"References_classified_by_therapeutic_area\">References classified by therapeutic area</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=20\" title=\"Edit section: References classified by therapeutic area\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span id=\"Chronic_obstructive_pulmonary_disease_.28COPD.29\"></span><span class=\"mw-headline\" id=\"Chronic_obstructive_pulmonary_disease_(COPD)\">Chronic obstructive pulmonary disease (COPD)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=21\" title=\"Edit section: Chronic obstructive pulmonary disease (COPD)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/CHMP/483572/2012 <i>Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)</i><sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup></li></ul>\n<h3><span class=\"mw-headline\" id=\"Diabetes_mellitus\">Diabetes mellitus</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=22\" title=\"Edit section: Diabetes mellitus\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>FDA: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup> provides recommendations for the development of drugs and therapeutic biologics regulated within the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Specifically, this guidance makes recommendations about how to demonstrate that a new antidiabetic therapy to treat type 2 diabetes is not associated with an unacceptable increase in cardiovascular risk.</li></ul>\n<h3><span id=\"Multiple_sclerosis_.28MS.29\"></span><span class=\"mw-headline\" id=\"Multiple_sclerosis_(MS)\">Multiple sclerosis (MS)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=23\" title=\"Edit section: Multiple sclerosis (MS)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>EMA/CHMP/771815/2011, Rev 2 <i>Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis</i><sup id=\"cite_ref-37\" class=\"reference\"><a href=\"#cite_note-37\">&#91;37&#93;</a></sup></li></ul>\n<h3><span class=\"mw-headline\" id=\"Oncology\">Oncology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=24\" title=\"Edit section: Oncology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>FDA: Clinical trial endpoints for the approval of cancer drugs and biologics<sup id=\"cite_ref-fda.gov_15-1\" class=\"reference\"><a href=\"#cite_note-fda.gov-15\">&#91;15&#93;</a></sup> provides recommendations to applicants on endpoints for cancer clinical trials submitted to the Food and Drug Administration (FDA) to support effectiveness claims in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.</li></ul>\n<h2><span id=\"References_classified_as_Health_Technology_Assessment_.28HTA.29\"></span><span class=\"mw-headline\" id=\"References_classified_as_Health_Technology_Assessment_(HTA)\">References classified as Health Technology Assessment (HTA)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=25\" title=\"Edit section: References classified as Health Technology Assessment (HTA)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"EUnetHTA_guidelines\">EUnetHTA guidelines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=26\" title=\"Edit section: EUnetHTA guidelines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The European Network for Health Technology Assessment (EUnetHTA) supports collaboration between several European HTA organizations. EUnetHTA Guidelines have been developed to help the assessors of evidence to process, analyse and interpret the data.\n</p>\n<ul><li>EUnetHTA: Endpoints used for Relative Effectiveness Assessment Clinical Endpoints. <sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup> This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA).</li>\n<li>EUnetHTA: Endpoints used for Relative Effectiveness Assessment Composite endpoints.  <sup id=\"cite_ref-39\" class=\"reference\"><a href=\"#cite_note-39\">&#91;39&#93;</a></sup> This guideline provides a set of recommendations and aspects to be considered for the assessment and interpretation of results of composite endpoints while performing relative effectiveness assessments.</li>\n<li>EUnetHTA: Endpoints used in Relative Effectiveness Assessment Surrogate Endpoints.  <sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup> This guideline is intended to provide guidance on when and how surrogate endpoints can be used for Relative Effectiveness Assessment (REA). The guideline is not intended to give a comprehensive list of validated surrogate endpoints and how well they predict final clinical endpoints.</li>\n<li>EUnetHTA: Endpoints used in Relative Effectiveness Assessment Safety.  <sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup> This guideline aims at providing a framework for the evaluation of relative safety performed by HTA assessors in the context of Relative Effectiveness Assessment (REA) .</li>\n<li>EUnetHTA: Endpoints used for Relative Effectiveness Assessment Health related quality of life and utility measures.  <sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup> This guideline encompasses \u201chealth-related quality of life\u201d (HRQoL) measures used for assessing HRQoL as one of the patient-reported outcomes of an intervention targeting morbidity reduction as well as HRQoL measures used in combination with life expectancy. As such, it relates mainly to the use of HRQoL measures in clinical trials. The perspective taken is that of the assessor of the relative effectiveness of an intervention in the context of a reimbursement request.</li>\n<li>EUnetHTA: Comparators &amp; Comparisons Criteria for the choice of the most appropriate comparator(s).  <sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup> This guideline is intended to summarise the available literature, the advice provided by existing national guidelines and the information from current national practice on the choice of comparator, and to outline some of the challenges arising when establishing what the comparator for a specific assessment should be.  It provides a set of internationally agreeable best practice recommendations for the selection of the most appropriate comparator when completing a REA.</li>\n<li>EUnetHTA: Comparators &amp; Comparisons Direct and indirect comparisons.  <sup id=\"cite_ref-44\" class=\"reference\"><a href=\"#cite_note-44\">&#91;44&#93;</a></sup> This guideline is intended to describe the main methods of direct, indirect and mixed treatment comparison available in terms of the types of relationship they can model and the assumptions inherent in them. The guideline is not intended to give a detailed understanding of the meta-analytic techniques described, but rather to explain the main strengths and weaknesses of the methodologies. The guideline discusses some common issues in meta-analysis that must be considered when interpreting results. Finally, the guideline provides a set of recommendations regarding the use of direct and indirect comparisons in a relative effectiveness assessment (REA).</li></ul>\n<h3><span class=\"mw-headline\" id=\"Methods_papers_of_HTA_agencies\">Methods papers of HTA agencies</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=27\" title=\"Edit section: Methods papers of HTA agencies\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<ul><li>IQWiG: General methods (version 5.0), Institute for Quality and Efficiency in Health Care, Cologne, Germany <sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup>. The IQWiG General Methods explain the legal and scientific basis of IQWiG and describe the tasks and the scientific tools applied by IQWiG in the preparation of its products.</li>\n<li>NICE: Guide to the methods of technology appraisal - Process and methods [PMG9] - Published date: April 2013 <sup id=\"cite_ref-46\" class=\"reference\"><a href=\"#cite_note-46\">&#91;46&#93;</a></sup>. National Institute for Health and Care Excellence, London, UK. The NICE Process and Methods Guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process. It describes key principles of appraisal methodology and is a guide for all organisations considering submitting evidence to the technology appraisal programme of the Institute.</li></ul>\n<h2><span class=\"mw-headline\" id=\"References_classified_as_country_specific\">References classified as country specific</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=28\" title=\"Edit section: References classified as country specific\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<table class=\"plainlinks metadata ambox mbox-small-left ambox-content\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><a href=\"/wiki/File:Wiki_letter_w_cropped.svg\" class=\"image\"><img alt=\"[icon]\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png\" width=\"20\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x\" data-file-width=\"44\" data-file-height=\"31\" /></a></td><td class=\"mbox-text\"><div class=\"mbox-text-span\"><b>This section is empty.</b> <small>You can help by <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=\">adding to it</a>.</small>  <small><i>(April 2017)</i></small></div></td></tr></tbody></table>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=29\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Guidances_for_statistics_in_regulatory_affairs\" title=\"Guidances for statistics in regulatory affairs\">Guidances for statistics in regulatory affairs</a></li>\n<li><a href=\"/wiki/Clinical_trials\" class=\"mw-redirect\" title=\"Clinical trials\">Clinical trials</a></li>\n<li><a href=\"/wiki/Medical_statistics\" title=\"Medical statistics\">Medical statistics</a></li>\n<li><a href=\"/wiki/Epidemiological_method\" title=\"Epidemiological method\">Epidemiological method</a></li>\n<li><a href=\"/wiki/Epidemiology\" title=\"Epidemiology\">Epidemiology</a></li>\n<li><a href=\"/wiki/Medicine\" title=\"Medicine\">Medicine</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=30\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf\">ICH E6(R2) - Good clinical practice (GCP)</a></span>\n</li>\n<li id=\"cite_note-FDA-GRP-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-FDA-GRP_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-FDA-GRP_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm377108.pdf\">FDA - Good Review Practice: Clinical Review of Investigational New Drug Applications</a></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001225.jsp&amp;mid=WC0b01ac05807d91a4\">CHMP/EWP/5872/03 Data monitoring committees</a></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm127073.pdf\">FDA - Establishment and Operation of Clinical Trial Data Monitoring Committees</a></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001217.jsp&amp;mid=WC0b01ac05807d91a4\">EMA/CHMP/295050/2013 Adjustment for baseline covariates in clinical trials</a></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001224.jsp&amp;mid=WC0b01ac05807d91a4\">CHMP/EWP/83561/05 Clinical trials in small populations</a></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf\"><i>Rare diseases: Common issues in drug development. Guidance for industry.</i></a> <span style=\"font-size:85%;\">(PDF)</span>, U.S. Department of Health and Human Services; Food and Drug Administration, 2015</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Rare+diseases%3A+Common+issues+in+drug+development.+Guidance+for+industry.&amp;rft.pub=U.S.+Department+of+Health+and+Human+Services%3B+Food+and+Drug+Administration&amp;rft.date=2015&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2FUCM458485.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/10/WC500236640.pdf\"><i>EMA/199678/2016 Reflection paper on extrapolation of efficacy and safety in paediatric medicine development</i></a> <span style=\"font-size:85%;\">(PDF)</span>, European Medicines Agency (EMA), 2017</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=EMA%2F199678%2F2016+Reflection+paper+on+extrapolation+of+efficacy+and+safety+in+paediatric+medicine+development&amp;rft.pub=European+Medicines+Agency+%28EMA%29&amp;rft.date=2017&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2017%2F10%2FWC500236640.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm444591.pdf\"><i>Leveraging existing clinical data for extrapolation to pediatric uses of medical devices</i></a> <span style=\"font-size:85%;\">(PDF)</span>, U.S. Department of Health and Human Services; Food and Drug Administration, 2015</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Leveraging+existing+clinical+data+for+extrapolation+to+pediatric+uses+of+medical+devices&amp;rft.pub=U.S.+Department+of+Health+and+Human+Services%3B+Food+and+Drug+Administration&amp;rft.date=2015&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2Fmedicaldevices%2Fdeviceregulationandguidance%2Fguidancedocuments%2Fucm444591.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ethnic-factors-in-the-acceptability-of-foreign-clinical-data.html\"><i>Ethnic factors in the acceptability of foreign clinical data</i></a>, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1998</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Ethnic+factors+in+the+acceptability+of+foreign+clinical+data&amp;rft.pub=International+Conference+on+Harmonization+of+Technical+Requirements+for+Registration+of+Pharmaceuticals+for+Human+Use&amp;rft.date=1998&amp;rft_id=http%3A%2F%2Fwww.ich.org%2Fproducts%2Fguidelines%2Fefficacy%2Fefficacy-single%2Farticle%2Fethnic-factors-in-the-acceptability-of-foreign-clinical-data.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf\"><i>Use of real-world evidence to support regulatory decision-making for medical devices</i></a> <span style=\"font-size:85%;\">(PDF)</span>, U.S. Department of Health and Human Services; Food and Drug Administration, 2017</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Use+of+real-world+evidence+to+support+regulatory+decision-making+for+medical+devices&amp;rft.pub=U.S.+Department+of+Health+and+Human+Services%3B+Food+and+Drug+Administration&amp;rft.date=2017&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2Fmedicaldevices%2Fdeviceregulationandguidance%2Fguidancedocuments%2Fucm513027.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001226.jsp&amp;mid=WC0b01ac05807d91a4\">CPMP/EWP/2158/99 Choice of a non-inferiority margin</a></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001623.jsp&amp;mid=WC0b01ac05807d91a4\">CPMP/EWP/482/99 Switching between superiority and non-inferiority</a></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001215.jsp&amp;mid=WC0b01ac05807d91a4\">EMA/CHMP/539146/2013 Investigation of subgroups in confirmatory clinical trials</a></span>\n</li>\n<li id=\"cite_note-fda.gov-15\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-fda.gov_15-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-fda.gov_15-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf\">FDA - Clinical trial endpoints for the approval of cancer drugs and biologics</a></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001227.jsp&amp;mid=WC0b01ac05807d91a4\">CPMP/EWP/2330/99 Application with 1. Meta-analyses; 2. One pivotal</a></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf\">ICH E1 - Population exposure: the extent of population exposure to assess clinical safety</a></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001219.jsp&amp;mid=WC0b01ac05807d91a4\">EMA/129698/2012 Extrapolation of efficacy and safety in medicine development</a></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001221.jsp&amp;mid=WC0b01ac05807d91a4\">CPMP/EWP/1776/99 Missing data in confirmatory clinical trials</a></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001220.jsp&amp;mid=WC0b01ac05807d91a4\">EMA/286914/2012 Multiplicity issues in clinical trials</a></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf\">ICH E3 - Structure and content of clinical study reports</a></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf\">FDA - Safety Reporting Requirements for INDs and BA/BE Studies</a></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079753.pdf\">FDA - Adverse Event Reporting to IRBs</a></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092257.pdf\">FDA - Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines</a></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2F/Step4/E2F_Step_4.pdf\">ICH E2F - Development Safety Update Report</a></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdf\">ICH E4 - Dose response information to support drug registration</a></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf\">ICH E5 (R1)- Ethnic factors in the acceptability of foreign clinical data</a></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf\">ICH E9 - Statistical Principles for Clinical Trials</a></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf\">ICH E10 - Choice of control group in clinical trials</a></span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001223.jsp&amp;mid=WC0b01ac05807d91a4\">CHMP/EWP/2459/02 Methodological issues in confirmatory clinical trials planned with an adaptive design</a></span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf\">FDA - Adaptive Design Clinical Trials for Drugs and Biologics</a></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf\">EMA - Guideline on bioanalytical method validation</a></span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf\">FDA - Evaluation of Sex-Specific Data in Medical Device Clinical Studies</a></span>\n</li>\n<li id=\"cite_note-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-34\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf\">ICH E7 - Studies in support of special populations: geriatrics</a></span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf\"><i>EMA/CHMP/483572/2012 Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)</i></a> <span style=\"font-size:85%;\">(PDF)</span>, European Medicines Agency (EMA), Respiratory Drafting Group, 2012</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=EMA%2FCHMP%2F483572%2F2012+Guideline+on+clinical+investigation+of+medicinal+products+in+the+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&amp;rft.pub=European+Medicines+Agency+%28EMA%29%2C+Respiratory+Drafting+Group&amp;rft.date=2012&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2012%2F08%2FWC500130880.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf\">FDA - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes</a></span>\n</li>\n<li id=\"cite_note-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-37\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf\"><i>EMA/CHMP/771815/2011, Rev 2 - Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis</i></a> <span style=\"font-size:85%;\">(PDF)</span>, European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), 2015</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=EMA%2FCHMP%2F771815%2F2011%2C+Rev+2+-+Guideline+on+clinical+investigation+of+medicinal+products+for+the+treatment+of+multiple+sclerosis&amp;rft.pub=European+Medicines+Agency+%28EMA%29%2C+Committee+for+Medicinal+Products+for+Human+Use+%28CHMP%29&amp;rft.date=2015&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2015%2F03%2FWC500185161.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eunethta.eu/sites/default/files/WP7-SG3-GL-clin_endpoints_amend2015.pdf\">EUnetHTA - Endpoints used for Relative Effectiveness Assessment Clinical Endpoints Amended JA1 Guideline Final Nov 2015</a></span>\n</li>\n<li id=\"cite_note-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-39\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20for%20Relative%20Effectiveness%20Assessment%20Composite%20endpoints_Amended%20JA1%20Guideline_Final%20Nov%202015_0.pdf\">EUnetHTA - Endpoints used for Relative Effectiveness Assessment Composite endpoints Amended JA1 Guideline Final Nov 2015</a></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20in%20Relative%20Effectiveness%20Assessment%20Surrogate%20Endpoints_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf\">EUnetHTA - Endpoints used in Relative Effectiveness Assessment Surrogate Endpoints Amended JA1 Guideline Final Nov 2015 </a></span>\n</li>\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/WP7-SG3-GL-safety_amend2015.pdf\">EUnetHTA - Endpoints used in Relative Effectiveness Assessment Safety Amended JA1 Guideline Final Nov 2015 </a></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20for%20Relative%20Effectiveness%20Assessment%20Health%20related%20quality%20of%20life%20and%20utility%20measures_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf\">EUnetHTA - Endpoints used for Relative Effectiveness Assessment Health related quality of life and utility measures Amended JA1 Guideline Final Nov 2015</a></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://eunethta.eu/sites/default/files/WP7-SG3-GL-choice_of_comparator_amend2015.pdf\">EUnetHTA - Comparators &amp; Comparisons Criteria for the choice of the most appropriate comparator(s) Amended JA1 Guideline 2015</a></span>\n</li>\n<li id=\"cite_note-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-44\">^</a></b></span> <span class=\"reference-text\"> <a rel=\"nofollow\" class=\"external text\" href=\"http://eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Comparators%20%26%20Comparisons%20%20Direct%20and%20indirect%20comparisons_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf\">EUnetHTA - Comparators &amp; Comparisons Direct and indirect comparisons Amended JA1 Guideline Final Nov 2015</a></span>\n</li>\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.iqwig.de/en/methods/methods-paper.3020.html\"><i>Allgemeine Methoden (General methods), version 5.0</i></a>, Cologne, Germany: Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG; Institute for Quality and Efficiency in Health Care), 10 July 2017, <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-3-9815265-2-3\" title=\"Special:BookSources/978-3-9815265-2-3\">978-3-9815265-2-3</a></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Allgemeine+Methoden+%28General+methods%29%2C+version+5.0&amp;rft.place=Cologne%2C+Germany&amp;rft.pub=Institut+f%C3%BCr+Qualit%C3%A4t+und+Wirtschaftlichkeit+im+Gesundheitswesen+%28IQWiG%3B+Institute+for+Quality+and+Efficiency+in+Health+Care%29&amp;rft.date=2017-07-10&amp;rft.isbn=978-3-9815265-2-3&amp;rft_id=https%3A%2F%2Fwww.iqwig.de%2Fen%2Fmethods%2Fmethods-paper.3020.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AList+of+Guidances+for+Statistics+in+Regulatory+Affairs\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-46\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.nice.org.uk/process/pmg9/chapter/foreword\">NICE - Process and methods (PMG9) Published date: April 2013</a> </span>\n</li>\n</ol></div></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=List_of_Guidances_for_Statistics_in_Regulatory_Affairs&amp;action=edit&amp;section=31\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html\">ICH Efficacy Guidelines</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000602.jsp&amp;mid=WC0b01ac05807d91a4\">European Medicines Agency\u2019s (EMA) scientific guidelines on biostatistics</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/RegulatoryInformation/Guidances/default.htm\">FDA Regulatory Information - Guidances</a></li></ul>\n<div role=\"navigation\" class=\"navbox\" aria-labelledby=\"Branches_of_life_science_and_biology\" style=\"padding:3px\"><table class=\"nowraplinks collapsible autocollapse navbox-inner\" style=\"border-spacing:0;background:transparent;color:inherit\"><tbody><tr><th scope=\"col\" class=\"navbox-title\" colspan=\"2\"><div class=\"plainlinks hlist navbar mini\"><ul><li class=\"nv-view\"><a href=\"/wiki/Template:Branches_of_biology\" title=\"Template:Branches of biology\"><abbr title=\"View this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">v</abbr></a></li><li class=\"nv-talk\"><a href=\"/wiki/Template_talk:Branches_of_biology\" title=\"Template talk:Branches of biology\"><abbr title=\"Discuss this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">t</abbr></a></li><li class=\"nv-edit\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Template:Branches_of_biology&amp;action=edit\"><abbr title=\"Edit this template\" style=\";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;\">e</abbr></a></li></ul></div><div id=\"Branches_of_life_science_and_biology\" style=\"font-size:114%;margin:0 4em\">Branches of <a href=\"/wiki/Life_science\" class=\"mw-redirect\" title=\"Life science\">life science</a> and <a href=\"/wiki/Biology\" title=\"Biology\">biology</a></div></th></tr><tr><td colspan=\"2\" class=\"navbox-list navbox-odd hlist\" style=\"width:100%;padding:0px\"><div style=\"padding:0em 0.25em\">\n<ul><li><a href=\"/wiki/Anatomy\" title=\"Anatomy\">Anatomy</a></li>\n<li><a href=\"/wiki/Astrobiology\" title=\"Astrobiology\">Astrobiology</a></li>\n<li><a href=\"/wiki/Biochemistry\" title=\"Biochemistry\">Biochemistry</a></li>\n<li><a href=\"/wiki/Biogeography\" title=\"Biogeography\">Biogeography</a></li>\n<li><a href=\"/wiki/Biohistory\" title=\"Biohistory\">Biohistory</a></li>\n<li><a href=\"/wiki/Biomechanics\" title=\"Biomechanics\">Biomechanics</a></li>\n<li><a href=\"/wiki/Biophysics\" title=\"Biophysics\">Biophysics</a></li>\n<li><a href=\"/wiki/Bioinformatics\" title=\"Bioinformatics\">Bioinformatics</a></li>\n<li><a href=\"/wiki/Biostatistics\" title=\"Biostatistics\">Biostatistics</a></li>\n<li><a href=\"/wiki/Botany\" title=\"Botany\">Botany</a></li>\n<li><a href=\"/wiki/Cell_biology\" title=\"Cell biology\">Cell biology</a></li>\n<li><a href=\"/wiki/Cellular_microbiology\" title=\"Cellular microbiology\">Cellular microbiology</a></li>\n<li><a href=\"/wiki/Chemical_biology\" title=\"Chemical biology\">Chemical biology</a></li>\n<li><a href=\"/wiki/Chronobiology\" title=\"Chronobiology\">Chronobiology</a></li>\n<li><a href=\"/wiki/Computational_biology\" title=\"Computational biology\">Computational biology</a></li>\n<li><a href=\"/wiki/Conservation_biology\" title=\"Conservation biology\">Conservation biology</a></li>\n<li><a href=\"/wiki/Cytogenetics\" title=\"Cytogenetics\">Cytogenetics</a></li>\n<li><a href=\"/wiki/Developmental_biology\" title=\"Developmental biology\">Developmental biology</a></li>\n<li><a href=\"/wiki/Ecology\" title=\"Ecology\">Ecology</a></li>\n<li><a href=\"/wiki/Embryology\" title=\"Embryology\">Embryology</a></li>\n<li><a href=\"/wiki/Epidemiology\" title=\"Epidemiology\">Epidemiology</a></li>\n<li><a href=\"/wiki/Epigenetics\" title=\"Epigenetics\">Epigenetics</a></li>\n<li><a href=\"/wiki/Evolutionary_biology\" title=\"Evolutionary biology\">Evolutionary biology</a></li>\n<li><a href=\"/wiki/Freshwater_biology\" title=\"Freshwater biology\">Freshwater biology</a></li>\n<li><a href=\"/wiki/Geobiology\" title=\"Geobiology\">Geobiology</a></li>\n<li><a href=\"/wiki/Genetics\" title=\"Genetics\">Genetics</a></li>\n<li><a href=\"/wiki/Genomics\" title=\"Genomics\">Genomics</a></li>\n<li><a href=\"/wiki/Histology\" title=\"Histology\">Histology</a></li>\n<li><a href=\"/wiki/Human_biology\" title=\"Human biology\">Human biology</a></li>\n<li><a href=\"/wiki/Immunology\" title=\"Immunology\">Immunology</a></li>\n<li><a href=\"/wiki/Marine_biology\" title=\"Marine biology\">Marine biology</a></li>\n<li><a href=\"/wiki/Mathematical_and_theoretical_biology\" title=\"Mathematical and theoretical biology\">Mathematical biology</a></li>\n<li><a href=\"/wiki/Microbiology\" title=\"Microbiology\">Microbiology</a></li>\n<li><a href=\"/wiki/Molecular_biology\" title=\"Molecular biology\">Molecular biology</a></li>\n<li><a href=\"/wiki/Mycology\" title=\"Mycology\">Mycology</a></li>\n<li><a href=\"/wiki/Neontology\" title=\"Neontology\">Neontology</a></li>\n<li><a href=\"/wiki/Neuroscience\" title=\"Neuroscience\">Neuroscience</a></li>\n<li><a href=\"/wiki/Nutrition\" title=\"Nutrition\">Nutrition</a></li>\n<li><a href=\"/wiki/Abiogenesis\" title=\"Abiogenesis\">Origin of life</a></li>\n<li><a href=\"/wiki/Paleontology\" title=\"Paleontology\">Paleontology</a></li>\n<li><a href=\"/wiki/Parasitology\" title=\"Parasitology\">Parasitology</a></li>\n<li><a href=\"/wiki/Pathology\" title=\"Pathology\">Pathology</a></li>\n<li><a href=\"/wiki/Pharmacology\" title=\"Pharmacology\">Pharmacology</a></li>\n<li><a href=\"/wiki/Phylogenetics\" title=\"Phylogenetics\">Phylogenetics</a></li>\n<li><a href=\"/wiki/Physiology\" title=\"Physiology\">Physiology</a></li>\n<li><a href=\"/wiki/Quantum_biology\" title=\"Quantum biology\">Quantum biology</a></li>\n<li><a href=\"/wiki/Sociobiology\" title=\"Sociobiology\">Sociobiology</a></li>\n<li><a href=\"/wiki/Structural_biology\" title=\"Structural biology\">Structural biology</a></li>\n<li><a href=\"/wiki/Systematics\" title=\"Systematics\">Systematics</a></li>\n<li><a href=\"/wiki/Systems_biology\" title=\"Systems biology\">Systems biology</a></li>\n<li><a href=\"/wiki/Biological_classification\" class=\"mw-redirect\" title=\"Biological classification\">Taxonomy</a></li>\n<li><a href=\"/wiki/Teratology\" title=\"Teratology\">Teratology</a></li>\n<li><a href=\"/wiki/Toxicology\" title=\"Toxicology\">Toxicology</a></li>\n<li><a href=\"/wiki/Virology\" title=\"Virology\">Virology</a></li>\n<li><a href=\"/wiki/Virophysics\" title=\"Virophysics\">Virophysics</a></li>\n<li><a href=\"/wiki/Zoology\" title=\"Zoology\">Zoology</a></li></ul>\n</div></td></tr></tbody></table></div>\n\n<!-- \nNewPP limit report\nParsed by mw2165\nCached time: 20180914113959\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.268 seconds\nReal time usage: 0.313 seconds\nPreprocessor visited node count: 976/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 34311/2097152 bytes\nTemplate argument size: 142/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 28440/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.074/10.000 seconds\nLua memory usage: 2.78 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  207.632      1 -total\n 55.21%  114.627      1 Template:Reflist\n 34.81%   72.270      8 Template:Citation\n 22.56%   46.836      1 Template:Empty_section\n 15.16%   31.483      1 Template:Ambox\n  6.81%   14.133      1 Template:Biology-footer\n  4.92%   10.207      1 Template:Navbox\n  2.01%    4.178      1 Template:Main_other\n  0.86%    1.785      1 Template:TOC_right\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:50970546-0!canonical and timestamp 20180914113959 and revision id 838265121\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_to_be_expanded_from_April_2017"},{"sortkey":"","hidden":"","*":"All_articles_to_be_expanded"},{"sortkey":"","hidden":"","*":"Articles_with_empty_sections_from_April_2017"},{"sortkey":"","hidden":"","*":"All_articles_with_empty_sections"},{"sortkey":"","hidden":"","*":"Articles_using_small_message_boxes"},{"sortkey":"*","*":"Biostatistics"},{"sortkey":"","*":"Clinical_trials"},{"sortkey":"","*":"Medical_statistics"}],"links":[{"ns":14,"exists":"","*":"Category:Articles to be expanded from April 2017"},{"ns":14,"exists":"","*":"Category:Articles with empty sections from April 2017"},{"ns":0,"exists":"","*":"List of Guidances for Statistics in Regulatory Affairs"},{"ns":0,"exists":"","*":"Abiogenesis"},{"ns":0,"exists":"","*":"Anatomy"},{"ns":0,"exists":"","*":"Astrobiology"},{"ns":0,"exists":"","*":"Biochemistry"},{"ns":0,"exists":"","*":"Biogeography"},{"ns":0,"exists":"","*":"Biohistory"},{"ns":0,"exists":"","*":"Bioinformatics"},{"ns":0,"exists":"","*":"Biological classification"},{"ns":0,"exists":"","*":"Biology"},{"ns":0,"exists":"","*":"Biomechanics"},{"ns":0,"exists":"","*":"Biophysics"},{"ns":0,"exists":"","*":"Biostatistics"},{"ns":0,"exists":"","*":"Botany"},{"ns":0,"exists":"","*":"Cell biology"},{"ns":0,"exists":"","*":"Cellular microbiology"},{"ns":0,"exists":"","*":"Chemical biology"},{"ns":0,"exists":"","*":"Chronobiology"},{"ns":0,"exists":"","*":"Clinical trials"},{"ns":0,"exists":"","*":"Computational biology"},{"ns":0,"exists":"","*":"Conservation biology"},{"ns":0,"exists":"","*":"Cytogenetics"},{"ns":0,"exists":"","*":"Developmental biology"},{"ns":0,"exists":"","*":"Ecology"},{"ns":0,"exists":"","*":"Embryology"},{"ns":0,"exists":"","*":"Epidemiological method"},{"ns":0,"exists":"","*":"Epidemiology"},{"ns":0,"exists":"","*":"Epigenetics"},{"ns":0,"exists":"","*":"Evolutionary biology"},{"ns":0,"exists":"","*":"Freshwater biology"},{"ns":0,"exists":"","*":"Genetics"},{"ns":0,"exists":"","*":"Genomics"},{"ns":0,"exists":"","*":"Geobiology"},{"ns":0,"exists":"","*":"Guidances for statistics in regulatory affairs"},{"ns":0,"exists":"","*":"Histology"},{"ns":0,"exists":"","*":"Human biology"},{"ns":0,"exists":"","*":"Immunology"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"Life science"},{"ns":0,"exists":"","*":"Marine biology"},{"ns":0,"exists":"","*":"Mathematical and theoretical biology"},{"ns":0,"exists":"","*":"Medical statistics"},{"ns":0,"exists":"","*":"Medicine"},{"ns":0,"exists":"","*":"Microbiology"},{"ns":0,"exists":"","*":"Molecular biology"},{"ns":0,"exists":"","*":"Mycology"},{"ns":0,"exists":"","*":"Neontology"},{"ns":0,"exists":"","*":"Neuroscience"},{"ns":0,"exists":"","*":"Nutrition"},{"ns":0,"exists":"","*":"Paleontology"},{"ns":0,"exists":"","*":"Parasitology"},{"ns":0,"exists":"","*":"Pathology"},{"ns":0,"exists":"","*":"Pharmacology"},{"ns":0,"exists":"","*":"Phylogenetics"},{"ns":0,"exists":"","*":"Physiology"},{"ns":0,"exists":"","*":"Quantum biology"},{"ns":0,"exists":"","*":"Sociobiology"},{"ns":0,"exists":"","*":"Structural biology"},{"ns":0,"exists":"","*":"Systematics"},{"ns":0,"exists":"","*":"Systems biology"},{"ns":0,"exists":"","*":"Teratology"},{"ns":0,"exists":"","*":"Toxicology"},{"ns":0,"exists":"","*":"Virology"},{"ns":0,"exists":"","*":"Virophysics"},{"ns":0,"exists":"","*":"Zoology"},{"ns":10,"exists":"","*":"Template:Branches of biology"},{"ns":11,"exists":"","*":"Template talk:Branches of biology"}],"templates":[{"ns":10,"exists":"","*":"Template:TOC right"},{"ns":10,"exists":"","*":"Template:Empty section"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Biology-footer"},{"ns":10,"exists":"","*":"Template:Branches of biology"},{"ns":10,"exists":"","*":"Template:Navbox"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Navbox"},{"ns":828,"exists":"","*":"Module:Navbar"}],"images":["Wiki_letter_w_cropped.svg"],"externallinks":["http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf","https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm377108.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001225.jsp&mid=WC0b01ac05807d91a4","https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm127073.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001217.jsp&mid=WC0b01ac05807d91a4","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001224.jsp&mid=WC0b01ac05807d91a4","https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/10/WC500236640.pdf","https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm444591.pdf","http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ethnic-factors-in-the-acceptability-of-foreign-clinical-data.html","https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001226.jsp&mid=WC0b01ac05807d91a4","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001623.jsp&mid=WC0b01ac05807d91a4","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001215.jsp&mid=WC0b01ac05807d91a4","http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001227.jsp&mid=WC0b01ac05807d91a4","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001219.jsp&mid=WC0b01ac05807d91a4","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001221.jsp&mid=WC0b01ac05807d91a4","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001220.jsp&mid=WC0b01ac05807d91a4","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf","https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf","https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079753.pdf","https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092257.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2F/Step4/E2F_Step_4.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001223.jsp&mid=WC0b01ac05807d91a4","https://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf","https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf","http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf","https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf","http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf","http://www.eunethta.eu/sites/default/files/WP7-SG3-GL-clin_endpoints_amend2015.pdf","http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20for%20Relative%20Effectiveness%20Assessment%20Composite%20endpoints_Amended%20JA1%20Guideline_Final%20Nov%202015_0.pdf","http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20in%20Relative%20Effectiveness%20Assessment%20Surrogate%20Endpoints_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf","http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/WP7-SG3-GL-safety_amend2015.pdf","http://www.eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Endpoints%20used%20for%20Relative%20Effectiveness%20Assessment%20Health%20related%20quality%20of%20life%20and%20utility%20measures_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf","http://eunethta.eu/sites/default/files/WP7-SG3-GL-choice_of_comparator_amend2015.pdf","http://eunethta.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/Comparators%20&%20Comparisons%20%20Direct%20and%20indirect%20comparisons_Amended%20JA1%20Guideline_Final%20Nov%202015.pdf","https://www.iqwig.de/en/methods/methods-paper.3020.html","https://www.nice.org.uk/process/pmg9/chapter/foreword","http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html","http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000602.jsp&mid=WC0b01ac05807d91a4","https://www.fda.gov/RegulatoryInformation/Guidances/default.htm"],"sections":[{"toclevel":1,"level":"2","line":"References classified by statistical topic","number":"1","index":"1","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":622,"anchor":"References_classified_by_statistical_topic"},{"toclevel":2,"level":"3","line":"Good clinical practice","number":"1.1","index":"2","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":671,"anchor":"Good_clinical_practice"},{"toclevel":2,"level":"3","line":"Data monitoring committees","number":"1.2","index":"3","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":1640,"anchor":"Data_monitoring_committees"},{"toclevel":2,"level":"3","line":"Adjustment by covariates","number":"1.3","index":"4","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":2613,"anchor":"Adjustment_by_covariates"},{"toclevel":2,"level":"3","line":"Small populations / rare diseases","number":"1.4","index":"5","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":3107,"anchor":"Small_populations_/_rare_diseases"},{"toclevel":2,"level":"3","line":"Extrapolation / bridging","number":"1.5","index":"6","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":4014,"anchor":"Extrapolation_/_bridging"},{"toclevel":2,"level":"3","line":"Non-inferiority","number":"1.6","index":"7","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":6218,"anchor":"Non-inferiority"},{"toclevel":2,"level":"3","line":"Subgroup analysis","number":"1.7","index":"8","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":7087,"anchor":"Subgroup_analysis"},{"toclevel":2,"level":"3","line":"Endpoints","number":"1.8","index":"9","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":7695,"anchor":"Endpoints"},{"toclevel":2,"level":"3","line":"Marketing authorization","number":"1.9","index":"10","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":8220,"anchor":"Marketing_authorization"},{"toclevel":2,"level":"3","line":"Missing data","number":"1.10","index":"11","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":9640,"anchor":"Missing_data"},{"toclevel":2,"level":"3","line":"Multiplicity","number":"1.11","index":"12","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":10205,"anchor":"Multiplicity"},{"toclevel":2,"level":"3","line":"Randomization","number":"1.12","index":"13","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":10609,"anchor":"Randomization"},{"toclevel":2,"level":"3","line":"Reporting","number":"1.13","index":"14","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":10784,"anchor":"Reporting"},{"toclevel":2,"level":"3","line":"Study design","number":"1.14","index":"15","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":13024,"anchor":"Study_design"},{"toclevel":2,"level":"3","line":"Method validation","number":"1.15","index":"16","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":15533,"anchor":"Method_validation"},{"toclevel":1,"level":"2","line":"References classified by special populations","number":"2","index":"17","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":15890,"anchor":"References_classified_by_special_populations"},{"toclevel":2,"level":"3","line":"Gender","number":"2.1","index":"18","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":15994,"anchor":"Gender"},{"toclevel":2,"level":"3","line":"Geriatrics","number":"2.2","index":"19","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":16376,"anchor":"Geriatrics"},{"toclevel":1,"level":"2","line":"References classified by therapeutic area","number":"3","index":"20","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":16899,"anchor":"References_classified_by_therapeutic_area"},{"toclevel":2,"level":"3","line":"Chronic obstructive pulmonary disease (COPD)","number":"3.1","index":"21","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":17001,"anchor":"Chronic_obstructive_pulmonary_disease_(COPD)"},{"toclevel":2,"level":"3","line":"Diabetes mellitus","number":"3.2","index":"22","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":17558,"anchor":"Diabetes_mellitus"},{"toclevel":2,"level":"3","line":"Multiple sclerosis (MS)","number":"3.3","index":"23","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":18308,"anchor":"Multiple_sclerosis_(MS)"},{"toclevel":2,"level":"3","line":"Oncology","number":"3.4","index":"24","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":18837,"anchor":"Oncology"},{"toclevel":1,"level":"2","line":"References classified as Health Technology Assessment (HTA)","number":"4","index":"25","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":19219,"anchor":"References_classified_as_Health_Technology_Assessment_(HTA)"},{"toclevel":2,"level":"3","line":"EUnetHTA guidelines","number":"4.1","index":"26","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":19284,"anchor":"EUnetHTA_guidelines"},{"toclevel":2,"level":"3","line":"Methods papers of HTA agencies","number":"4.2","index":"27","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":24735,"anchor":"Methods_papers_of_HTA_agencies"},{"toclevel":1,"level":"2","line":"References classified as country specific","number":"5","index":"28","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":26077,"anchor":"References_classified_as_country_specific"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"29","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":26161,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"30","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":26338,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"8","index":"31","fromtitle":"List_of_Guidances_for_Statistics_in_Regulatory_Affairs","byteoffset":26497,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"List of Guidances for Statistics in Regulatory Affairs","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q30314043"}]}}